Abstract:Yes-associated protein (YAP) is a significant downstream protein in the Hippo signaling pathway with important functions in cell proliferation, apoptosis, invasion and migration. YAP also plays a role in the progression and development of various liver diseases. In hepatic fibrosis development and reversion, the proliferation and apoptosis of activated hepatic stellate cells (HSCs) play a critical role. However, the contribution of YAP to hepatic fibrosis progression and reversion and the underlying mechanism have not been investigated. Here we investigated the expression and function of YAP in the proliferation and apoptosis of activated HSCs. We found that YAP expression was increased in liver fibrosis tissues from CCl4-induced model mice and restored to normal level after stopping CCl4 injection and 6 weeks of spontaneously recovery. YAP expression was elevated in HSC-T6 cells treated with TGF-β1 and recovered after MDI treatment. Silencing of YAP inhibited the activation and proliferation of HSC-T6 cells stimulated by TGF-β1. In addition, the apoptosis of activated HSC-T6 cells silenced for YAP was slightly enhanced. Furthermore, over-expression of YAP repressed the reversion of activated HSC-T6 cells mediated by MDI reversal. We found that HSC-T6 cells activated by TGF-β1 showed higher levels of nuclear YAP compared with MDI-treated cells, indicating that YAP was activated in HSC-T6 cells treated by TGF-β1. We also found that loss of YAP attenuated Wnt/β-catenin pathway activity in activated HSC-T6 cells. Treatment of VP, an inhibitor of the YAP-TEAD complex, reduced both activation and proliferation of HSC-T6 cells and increased apoptosis. Together these results indicated that reduced expression of YAP contributes to acquisition of the quiescent phenotype in HSCs. Our results suggest that YAP may be a useful target in HSCs activation and reversion.

Phosphorylated Ezrin (thr567) Regulates Hippo Pathway and Yes-Associated Protein (yap) in Liver

Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells.

Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Acetylation of Ezrin Regulates Membrane-Cytoskeleton Interaction Underlying CCL18-elicited Cell Migration.

A Coordinated Phosphorylation By Lats And Ck1 Regulates Yap Stability Through Scf Beta-Trcp

Integration of Hippo Signalling and the Unfolded Protein Response to Restrain Liver Overgrowth and Tumorigenesis

Yes-Associated Protein Impacts Adherens Junction Assembly Through Regulating Actin Cytoskeleton Organization

Inactivation of Yap Oncoprotein by the Hippo Pathway is Involved in Cell Contact Inhibition and Tissue Growth Control

Yes-associated protein promotes the proliferation and differentiation of liver progenitor cells during liver fibrosis.

Mutual Interaction Between Yap and Creb Promotes Tumorigenesis in Liver Cancer

Hippo Signalling Governs Cytosolic Nucleic Acid Sensing Through Yap/Taz-Mediated Tbk1 Blockade

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

Hepatitis B Virus X Protein Modulates Oncogene Yes-Associated Protein By Creb To Promote Growth Of Hepatoma Cells

Yes-associated Protein Promotes Early Hepatocyte Cell Cycle Progression in Regenerating Liver after Tissue Loss.

CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer

Ezrin Promotes Esophageal Squamous Cell Carcinoma Progression Via the Hippo Signaling Pathway.

Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma

The Hippo/YAP Pathway Interacts with EGFR Signaling and HPV Oncoproteins to Regulate Cervical Cancer Progression.

Ezrin promotes hepatocellular carcinoma progression by modulating glycolytic reprogramming

Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication

Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways